Generics versus biosimilars: pricing and usage-enhancing policies

Posted 23/02/2018

In Europe, pricing and demand-side measures for generic medicines are widely implemented and have undergone evaluations [1-4].  However, when it comes t...

Biosimilars of denosumab Biosimilars/General | Posted 23/02/2018
Canada’s generics industry to cut prices by up... Generics/General | Posted 23/02/2018
Persistence with generic imatinib in CML patients Generics/Research | Posted 23/02/2018
Etanercept switching study investigates non-man... Biosimilars/Research | Posted 23/02/2018
EBE reveals Europe’s biosimilar pricing and rei... Biosimilars/Research | Posted 15/02/2018
EMA approval for biosimilar insulin glargine Se... Biosimilars/News | Posted 15/02/2018
Quality and clinical performance of biopharmace... Biosimilars/Research | Posted 15/02/2018
Building confidence in biosimilars Reports | Posted 15/02/2018
Europe calls for more drugs repurposing Generics/General | Posted 15/02/2018
Efficacy and safety of generic imatinib after s... Generics/Research | Posted 15/02/2018
Zarxio reveals all: the US biosimilars market Biosimilars/Research | Posted 09/02/2018
Comments on TGA’s modified approach to naming b... Policies & Legislation | Posted 09/02/2018
Quebec adds biosimilar etanercept Erelzi to pub... Biosimilars/General | Posted 09/02/2018
Approval rating and opinion on generic drugs in... Generics/Research | Posted 09/02/2018
Structure-function relationship between disulfi... Biosimilars/Research | Posted 09/02/2018
Denosumab biosimilar being developed in Australia Biosimilars/News | Posted 09/02/2018
Medicines for Europe 14th Legal Affairs Conference Conferences | Posted 09/02/2018
Medicines for Europe 16th Biosimilar Medicines... Conferences | Posted 09/02/2018
The biosimilar landscape in Italy revealed Biosimilars/Research | Posted 02/02/2018
Interchangeability of gabapentin generics Generics/Research | Posted 02/02/2018
EC approval for bevacizumab biosimilar Mvasi Biosimilars/News | Posted 02/02/2018
FDA accepts applications for adalimumab and tra... Biosimilars/News | Posted 02/02/2018
Danish etanercept switching study investigates... Biosimilars/Research | Posted 02/02/2018
FDA denies Novo Nordisk petition to block gener... Generics/General | Posted 02/02/2018
Hospitals to start own generics company Generics/News | Posted 26/01/2018
France aims to reach 80% biosimilar penetration... Policies & Legislation | Posted 26/01/2018
Mylan/Momenta announce development strategy for... Biosimilars/General | Posted 26/01/2018
Trastuzumab biosimilars receive EMA and ANVISA... Biosimilars/News | Posted 26/01/2018
Switching to biosimilars in rheumatology Biosimilars/Research | Posted 26/01/2018
EMA accepts application for pegfilgrastim biosi... Biosimilars/News | Posted 26/01/2018
Biosimilars applications under review by EMA –... Biosimilars/General | Posted 19/01/2018
Additional clinical data for Cinfa’s pegfilgras... Biosimilars/Research | Posted 19/01/2018
Treatment of chronic myeloid leukaemia patients... Generics/Research | Posted 19/01/2018
FDA approves follow-on insulin lispro Admelog Biosimilars/News | Posted 19/01/2018
France fines J&J 25 million Euro for blocki... Generics/General | Posted 19/01/2018
Mylan appeals to FDA: no approval for generic A... Generics/News | Posted 19/01/2018
Top 10 most read GaBI Online articles in 2017 Pharma News | Posted 12/01/2018


Mylan launches first follow-on glatiramer acetate in the UK Posted 15/02/2018

US generics giant Mylan announced on 23 January 2018 that it had launched Bra...


Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 05/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015

Generics News Research General


Biosimilars News Research General